A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Deep neuromuscular blockade during certain surgical procedures may improve operating conditions. Sugammadex can be used to reverse deep neuromuscular blockade without waiting for spontaneous recovery. This randomised study compared recovery times from neuromuscular blockade induced by rocuronium 0.6 mg.kg(-1), using sugammadex 4 mg.kg(-1) administered at 1-2 post-tetanic count (deep blockade) or neostigmine 50 μg.kg(-1) (plus atropine 10 μg.kg(-1)) administered at the re-appearance of the second twitch of a train-of-four stimulation (moderate blockade), in patients undergoing laparoscopic surgery. The primary efficacy variable was the time from the start of sugammadex/neostigmine administration to recovery of the train-of-four ratio to 0.9. Patients receiving sugammadex recovered 3.4 times faster than patients receiving neostigmine (geometric mean (95% CI) recovery times of 2.4 (2.1-2.7) and 8.4 (7.2-9.8) min, respectively, p<0.0001). Moreover, 94% (62/66) of sugammadex-treated patients recovered within 5 min, vs 20% (13/65) of neostigmine-treated patients, despite the difference in the depth of neuromuscular blockade at the time of administration of both drugs. The ability to provide deep neuromuscular blockade throughout the procedure but still permit reversal at the end of surgery may enable improved surgical access and an enhanced visual field.
Department of Anaesthesiology, Klinikum Ludwigsburg, Academic Teaching Hospital, University of Heidelberg, Ludwigsburg, Germany. goetz.geldner@kliniken-lb.de
G
G
Geldner
M
M
Niskanen
P
P
Laurila
V
V
Mizikov
M
M
Hübler
G
G
Beck
H
H
Rietbergen
E
E
Nicolayenko
D000328:Adult; D000368:Aged; D000732:Androstanols / Q000037:antagonists & inhibitors; D000758:Anesthesia; D000762:Anesthesia Recovery Period; D018686:Anesthetics, Intravenous; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004558:Electric Stimulation; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D010535:Laparoscopy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000009:adverse effects / Q000627:therapeutic use*; D019148:Neuromuscular Blockade / Q000379:methods*; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors; D061214:Patient Safety; D015742:Propofol; D000077123:Rocuronium; D018401:Sample Size; D000077122:Sugammadex; D014673:Vecuronium Bromide / Q000037:antagonists & inhibitors; D055815:Young Adult; D047408:gamma-Cyclodextrins / Q000009:adverse effects / Q000627:therapeutic use*
D000732:Androstanols; D018686:Anesthetics, Intravenous; D002800:Cholinesterase Inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D009388:Neostigmine; D014673:Vecuronium Bromide; D000077123:Rocuronium; D015742:Propofol